Associated Papers
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A et al.
Nature Communications, 2023
36922497 (PubMed )
Supplement: 41467_2023_37084_MOESM1_ESM.pdf
Select a paper to view details